• Je něco špatně v tomto záznamu ?

EWSR1-SMAD3-rearranged Fibroblastic Tumor: An Emerging Entity in an Increasingly More Complex Group of Fibroblastic/Myofibroblastic Neoplasms

M. Michal, RS. Berry, BP. Rubin, SE. Kilpatrick, A. Agaimy, DV. Kazakov, P. Steiner, N. Ptakova, P. Martinek, L. Hadravsky, K. Michalova, Z. Szep, M. Michal,

. 2018 ; 42 (10) : 1325-1333. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu kazuistiky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035154

Three cases of superficial acral fibroblastic spindle cell neoplasms with EWSR1-SMAD3 fusion have been recently reported. Their differential diagnosis is broad, primarily comprising rare tumors from the fibroblastic/myofibroblastic category. The aim of this report is to present 4 new cases of this entity and to discuss the appropriate differential diagnosis. Also, as the ERG antibody seems to be a characteristic marker for these tumors, we analyzed ERG immunostaining characteristics in potential mimics of this entity. All cases in our cohort occurred in women aged 5 to 68 years (mean, 36.5 y). Two were located on the hand, 1 on foot, and the last case arose on the calf. The tumor size ranged from 1 to 1.5 cm in the greatest dimension, with a mean size of 1.2 cm. Except for one recent case, follow-up was available, ranging from 7 to 18 years (mean, 11.7 y), with a recurrence noted in 1 case after 10 years. All tumors were subcutaneous and showed 2 main components. One consisted of bland, spindled cells with elongated nuclei which were round when observed on the cross-section. These cells mostly grew in relatively hypercellular, well-organized, and intersecting fascicles. The second component was prominently hyalinized and paucicellular, but lacked calcifications. Both components showed either a distinct zonation pattern, or they were randomly intermingled with each other. In all 3 analyzable tumors, next-generation sequencing showed EWSR1-SMAD3 gene fusion in each case. By fluorescence in situ hybridization, one tested case also revealed unbalanced rearrangement of the EWSR1 gene. All 4 cases showed strong, diffuse nuclear expression of ERG, whereas none of the mimics stained with this antibody except for weak to moderate staining in calcifying aponeurotic fibromas (9/10 cases). Two tumors showed focal weak to moderate expression of SAT-B2. The 4 herein presented cases further broaden the clinicopathologic spectrum of tumors with EWSR1-SMAD3 gene fusion. They also confirm that they represent a novel entity for which we propose the name EWSR1-SMAD3-rearranged fibroblastic Tumor. Our study also proves that in the context of fibroblastic/myofibroblastic tumors, ERG immunohistochemistry is a relatively specific marker for these neoplasms.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035154
003      
CZ-PrNML
005      
20191008095801.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/PAS.0000000000001109 $2 doi
035    __
$a (PubMed)29957732
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Michal, Michael $u Department of Pathology. Biomedical Center, Charles University Faculty of Medicine in Pilsen. Bioptical Laboratory Ltd, Pilsen.
245    10
$a EWSR1-SMAD3-rearranged Fibroblastic Tumor: An Emerging Entity in an Increasingly More Complex Group of Fibroblastic/Myofibroblastic Neoplasms / $c M. Michal, RS. Berry, BP. Rubin, SE. Kilpatrick, A. Agaimy, DV. Kazakov, P. Steiner, N. Ptakova, P. Martinek, L. Hadravsky, K. Michalova, Z. Szep, M. Michal,
520    9_
$a Three cases of superficial acral fibroblastic spindle cell neoplasms with EWSR1-SMAD3 fusion have been recently reported. Their differential diagnosis is broad, primarily comprising rare tumors from the fibroblastic/myofibroblastic category. The aim of this report is to present 4 new cases of this entity and to discuss the appropriate differential diagnosis. Also, as the ERG antibody seems to be a characteristic marker for these tumors, we analyzed ERG immunostaining characteristics in potential mimics of this entity. All cases in our cohort occurred in women aged 5 to 68 years (mean, 36.5 y). Two were located on the hand, 1 on foot, and the last case arose on the calf. The tumor size ranged from 1 to 1.5 cm in the greatest dimension, with a mean size of 1.2 cm. Except for one recent case, follow-up was available, ranging from 7 to 18 years (mean, 11.7 y), with a recurrence noted in 1 case after 10 years. All tumors were subcutaneous and showed 2 main components. One consisted of bland, spindled cells with elongated nuclei which were round when observed on the cross-section. These cells mostly grew in relatively hypercellular, well-organized, and intersecting fascicles. The second component was prominently hyalinized and paucicellular, but lacked calcifications. Both components showed either a distinct zonation pattern, or they were randomly intermingled with each other. In all 3 analyzable tumors, next-generation sequencing showed EWSR1-SMAD3 gene fusion in each case. By fluorescence in situ hybridization, one tested case also revealed unbalanced rearrangement of the EWSR1 gene. All 4 cases showed strong, diffuse nuclear expression of ERG, whereas none of the mimics stained with this antibody except for weak to moderate staining in calcifying aponeurotic fibromas (9/10 cases). Two tumors showed focal weak to moderate expression of SAT-B2. The 4 herein presented cases further broaden the clinicopathologic spectrum of tumors with EWSR1-SMAD3 gene fusion. They also confirm that they represent a novel entity for which we propose the name EWSR1-SMAD3-rearranged fibroblastic Tumor. Our study also proves that in the context of fibroblastic/myofibroblastic tumors, ERG immunohistochemistry is a relatively specific marker for these neoplasms.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x analýza $x genetika $7 D014408
650    _2
$a biopsie $7 D001706
650    _2
$a fibroblasty asociované s nádorem $x chemie $x patologie $7 D000072645
650    _2
$a předškolní dítě $7 D002675
650    _2
$a ženské pohlaví $7 D005260
650    12
$a fúze genů $7 D050939
650    12
$a genová přestavba $7 D015321
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a myofibroblasty $x chemie $x patologie $7 D058628
650    _2
$a nádory z pojivové a měkké tkáně $x chemie $x genetika $x patologie $x chirurgie $7 D018204
650    _2
$a fenotyp $7 D010641
650    _2
$a protein EWS vázající RNA $x genetika $7 D034802
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a protein Smad3 $x genetika $7 D051900
650    _2
$a transkripční regulátor ERG $x analýza $7 D000071230
650    _2
$a výsledek terapie $7 D016896
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Berry, Ryan S $u Department of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.
700    1_
$a Rubin, Brian P $u Department of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.
700    1_
$a Kilpatrick, Scott E $u Department of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.
700    1_
$a Agaimy, Abbas $u Institute of Pathology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
700    1_
$a Kazakov, Dmitry V $u Department of Pathology. Bioptical Laboratory Ltd, Pilsen.
700    1_
$a Steiner, Petr $u Department of Pathology. Bioptical Laboratory Ltd, Pilsen.
700    1_
$a Ptakova, Nikola $u Department of Pathology. Bioptical Laboratory Ltd, Pilsen.
700    1_
$a Martinek, Petr $u Department of Pathology. Bioptical Laboratory Ltd, Pilsen.
700    1_
$a Hadravsky, Ladislav $u Department of Pathology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Michalova, Kvetoslava $u Department of Pathology. Bioptical Laboratory Ltd, Pilsen.
700    1_
$a Szep, Zoltan $u Cytopathos Ltd, Bratislava, Slovakia.
700    1_
$a Michal, Michal $u Department of Pathology. Bioptical Laboratory Ltd, Pilsen.
773    0_
$w MED00000304 $t The American journal of surgical pathology $x 1532-0979 $g Roč. 42, č. 10 (2018), s. 1325-1333
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29957732 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191008100217 $b ABA008
999    __
$a ok $b bmc $g 1451814 $s 1073704
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 42 $c 10 $d 1325-1333 $e - $i 1532-0979 $m The American journal of surgical pathology $n Am J Surg Pathol $x MED00000304
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace